GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Book Value per Share

Shield Therapeutics (LSE:STX) Book Value per Share : £0.04 (As of Jun. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics Book Value per Share?

Shield Therapeutics's book value per share for the quarter that ended in Jun. 2023 was £0.04.

During the past 12 months, Shield Therapeutics's average Book Value Per Share Growth Rate was -74.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -57.10% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -36.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Shield Therapeutics was -10.10% per year. The lowest was -57.10% per year. And the median was -16.75% per year.

Shield Therapeutics's current price is £0.02. Its book value per share for the quarter that ended in Jun. 2023 was £0.04. Hence, today's PB Ratio of Shield Therapeutics is 0.95.

During the past 9 years, the highest P/B Ratio of Shield Therapeutics was 6.57. The lowest was 0.31. And the median was 2.75.


Shield Therapeutics Book Value per Share Historical Data

The historical data trend for Shield Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics Book Value per Share Chart

Shield Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Book Value per Share
Get a 7-Day Free Trial Premium Member Only 0.34 0.27 0.25 0.18 0.02

Shield Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.18 0.15 0.02 0.04

Competitive Comparison of Shield Therapeutics's Book Value per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shield Therapeutics's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's PB Ratio falls into.



Shield Therapeutics Book Value per Share Calculation

Shield Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2022 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(5.43-0.00)/259.39
=0.02

Shield Therapeutics's Book Value Per Share for the quarter that ended in Jun. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(27.10-0.00)/713.04
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Shield Therapeutics  (LSE:STX) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Shield Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Shield Therapeutics (LSE:STX) Business Description

Traded in Other Exchanges
Address
Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.